# Doron Aspitz

> Doron Aspitz is the President and CEO of Verix, a Santa Clara-based AI platform that helps pharmaceutical companies optimize their commercial operations through predictive analytics, HCP targeting, and GenAI-powered decision intelligence. A serial entrepreneur with 20+ years in technology leadership, he previously co-founded Blue Pumpkin Software - a workforce management company acquired by Witness Systems for ~$75 million in 2005. At Verix, he has built the Tovana platform, now trusted by global pharma giants including Bayer, Novartis, Roche, and GSK, bringing AI-driven commercial intelligence to the complex world of drug commercialization.

- **Role:** President & CEO at Verix
- **Organizations:** Verix, Blue Pumpkin Software, Tandem Corporation, IBM
- **Nationality:** Israeli-American
- **Education:** Master's in Management Information Systems (MIS), Tel Aviv University, B.Sc. in Economics and Statistics, Tel Aviv University
- **Known for:** Co-founded Blue Pumpkin Software, leading it to a ~$75 million acquisition by Witness Systems in 2005, Won 'Pioneer of the Year' award from Call Center Magazine, Built Verix Tovana platform used by global pharma leaders including Bayer, Novartis, Roche, and GSK

## Career timeline

- **Early career** — Senior technical and business management roles at IBM and Tandem Corporation
- **2000** — Co-founded Blue Pumpkin Software, a workforce management solutions company for contact centers
- **2004** — Led Blue Pumpkin Software through strong growth and profitability despite difficult market conditions; won Pioneer of the Year from Call Center Magazine
- **2005-01** — Blue Pumpkin Software acquired by Witness Systems (NASDAQ: WITS) for approximately $75 million
- **2004** — Founded Verix, a pharmaceutical commercial analytics platform
- **2019-08** — Verix raised convertible note funding, bringing total raised to $12.7M
- **2023** — Verix acquired start-up.ai to enhance AI and LLM capabilities for life sciences
- **2024-03** — Launched GenAI Database Explorer on Verix Tovana platform
- **2025-11** — Citius Oncology partnership for commercial launch of LYMPHIR using Verix Tovana platform
- **2026** — Recognized as Top AI-Powered Pharma Platform 2026 by Pharma Tech Outlook

## Achievements

- Co-founded Blue Pumpkin Software, leading it to a ~$75 million acquisition by Witness Systems in 2005
- Won 'Pioneer of the Year' award from Call Center Magazine
- Built Verix Tovana platform used by global pharma leaders including Bayer, Novartis, Roche, and GSK
- Grew Verix to 63 employees with ~$3.5M annual revenue on $12.7M total funding
- Launched pharma-specific GenAI Database Explorer in 2024, enabling natural language querying of commercial data
- Acquired AI specialist firm start-up.ai to build life-science-trained LLMs
- Achieved reported ~4X ROI for clients within first year of Tovana platform deployment
- Recognized by Pharma Tech Outlook as Top AI-Powered Pharma Platform 2026

## Latest updates

- **2026-05** — Verix named Top AI-Powered Pharma Platform 2026 by Pharma Tech Outlook
- **2025-11** — Citius Oncology selects Verix Tovana platform to support commercial launch of LYMPHIR (denileukin diftitox-cxdl)
- **2024-03** — Verix launches GenAI Database Explorer, enabling pharma teams to query commercial data in natural language
- **2023** — Verix acquires start-up.ai to enhance life sciences AI and LLM capabilities

## Links

- Website: https://verix.com
- LinkedIn: http://www.linkedin.com/in/doron-aspitz
- Twitter/X: https://twitter.com/aspitz
- Facebook: https://www.facebook.com/doron.aspitz.9

---

Profile page: https://yespress.io/doron-aspitz
Published by YesPress — https://yespress.io
Last updated: 2026-05-17